Dishevelled binding antagonist of beta catenin 2 (DACT2)

Dishevelled binding antagonist of beta catenin 2 (DACT2) is a protein encoded by the **DACT2 gene** in humans and functions as a tumor suppressor through inhibition of the Wnt/β-catenin signaling pathway[1][2][3]. DACT2 interacts directly with β-catenin and is involved in cytoplasmic retention as well as disruption of the β-catenin–LEF1 complex in the nucleus, thereby regulating gene transcription and cell fate. DACT2 also negatively regulates Nodal signaling, possibly by promoting lysosomal degradation of Nodal receptors such as TGFBR1, and plays a role in developmental processes, including epithelial cell morphogenesis and ureteric bud development[2][5]. In cancers such as colon cancer, DACT2 expression is frequently silenced by promoter hypermethylation, and loss of DACT2 correlates with poorer patient survival[1]. There are currently no drugs targeting DACT2 directly, but its epigenetic status (methylation) has value as a biomarker for prognosis in colon cancer[1][2].

Other names

Dapper homolog 2C6orf116PP13671bA503C24.7DAPPER2Dapper antagonist of catenin 2DPR2

Not applicable; no approved drugs or clinical agents are known to directly target DACT2 as of current knowledge